ANRO
Alto Neuroscience Inc.

1,099
Mkt Cap
$482.77M
Volume
227,647.00
52W High
$15.78
52W Low
$1.60
PE Ratio
-6.75
ANRO Fundamentals
Price
$15.17
Prev Close
$15.54
Open
$15.35
50D MA
$8.36
Beta
1.72
Avg. Volume
4.01M
EPS (Annual)
-$2.50
P/B
3.78
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
read more...
Benzinga·3d ago
News Placeholder
More News
News Placeholder
Alto Neuroscience (NYSE:ANRO) Upgraded at Wall Street Zen
Wall Street Zen upgraded Alto Neuroscience from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat·4d ago
News Placeholder
Is Alto Neuroscience, Inc. (ANRO) Outperforming Other Medical Stocks This Year?
Here is how Alto Neuroscience, Inc. (ANRO) and Editas Medicine (EDIT) have performed compared to their sector so far this year.
Zacks·6d ago
News Placeholder
Robert W. Baird Issues Positive Forecast for Alto Neuroscience (NYSE:ANRO) Stock Price
Robert W. Baird raised their price objective on Alto Neuroscience from $16.00 to $22.00 and gave the company an "outperform" rating in a report on Thursday...
MarketBeat·6d ago
News Placeholder
Jefferies Financial Group Forecasts Strong Price Appreciation for Alto Neuroscience (NYSE:ANRO) Stock
Jefferies Financial Group upped their price target on Alto Neuroscience from $15.00 to $25.00 and gave the stock a "buy" rating in a research note on Wednesday...
MarketBeat·7d ago
News Placeholder
Alto Neuroscience (NYSE:ANRO) Issues Earnings Results
Alto Neuroscience (NYSE:ANRO - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts' consensus...
MarketBeat·7d ago
News Placeholder
Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial...
Business Wire·8d ago
News Placeholder
NYSE Content Advisory: Pre-Market Update + Government Shutdown Nears End After 42 Days
NYSE Content Advisory: Pre-Market Update + Government Shutdown Nears End After 42 Days NYSE Content Advisory: Pre-Market Update + Government Shutdown Nears End After 42 Days PR Newswire NEW YORK...
PR Newswire·9d ago
News Placeholder
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?
Alto Neuroscience, Autolus Therapeutics, Ascendis Pharma and Immuneering are gearing up to report Q3 results that could top expectations.
Zacks·10d ago
News Placeholder
How Much Upside is Left in Alto Neuroscience, Inc. (ANRO)? Wall Street Analysts Think 61.99%
The consensus price target hints at a 62% upside potential for Alto Neuroscience, Inc. (ANRO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·10d ago

Latest ANRO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.